Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Yumanity Therapeutics Inc. YMTX

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.


Recent & Breaking News (NDAQ:YMTX)

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

GlobeNewswire 6 days ago

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, CVET, YMTX

PR Newswire July 6, 2022

YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Yumanity Therapeutics, Inc. - YMTX

Business Wire July 5, 2022

YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Yumanity Therapeutics, Inc. - YMTX

Business Wire June 7, 2022

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates YMTX, GTYH, HR, POLY

PR Newswire June 7, 2022

Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

GlobeNewswire June 6, 2022

Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments

GlobeNewswire May 12, 2022

Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments

GlobeNewswire March 24, 2022

Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring

GlobeNewswire February 17, 2022

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 4, 2022

Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739  

GlobeNewswire January 19, 2022

Yumanity's Approach to Neurodegenerative Diseases Validated by Two External Collaborations

GlobeNewswire January 11, 2022

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 5, 2022

Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference

GlobeNewswire January 4, 2022

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 3, 2021

Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences

GlobeNewswire November 16, 2021

Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

GlobeNewswire November 15, 2021

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 12, 2021

Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson's Disease; Company Plans to Advance Program to Phase 2

GlobeNewswire November 10, 2021

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 14, 2021